S
SciRhom
Developing a new treatment for autoimmune diseases
About SciRhom
Scirhom is a biotechnology company focused on developing innovative therapies targeting iRhom2, an inactive rhomboid protease. The company aims to address unmet medical needs in the fields of immunology, inflammation, oncology, infectious, and metabolic diseases. By inhibiting iRhom2, Scirhom seeks to selectively target the pro-inflammatory functions of TACE (Tumor Necrosis Factor-Alpha Converting Enzyme) without causing the severe side effects associated with direct TACE inhibition. This approach offers a promising alternative for treating conditions such as rheumatoid arthritis, hemophilia-induced inflammatory arthritis, and systemic lupus erythematosus. Scirhom's business model revolves around research and development, with a focus on preclinical and clinical trials to validate the efficacy and safety of their iRhom2 inhibitors. The company generates revenue through partnerships, licensing agreements, and potential future sales of approved therapies. Scirhom serves pharmaceutical companies, healthcare providers, and patients seeking advanced treatments for chronic inflammatory and autoimmune diseases.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jul 2024 | $69M | $277M | HTGF · Wellington Partners · MIG Capital · Andera Partners | ↗ |
| SEEDOther financing | Nov 2021 | $8.8M | $35M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for SciRhom is 330 monthly website visits, down 5.7% over the last three months. SciRhom's team declined 5.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
SciRhom in the Planegg ecosystem
The SciRhom office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Wellington Partners
MIG Capital
Andera Partners
Hadean Ventures
Kurma Partners
HTGF
Bayern Kapital
PhiFund Ventures
Other known investors1 additional known investor
Innovation and Start-Up Center for Biotechnology (IZB)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SciRhom on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SciRhom’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










